

Special Issue

Breast Cancer Research and Treatment

Message from the Guest Editor

Breast cancer is classified into four molecular subtypes: luminal A, luminal B, triple-negative breast cancer (TNBC), and human epidermal growth factor receptor type 2 (HER2)-positive. The tumor microenvironment plays a critical role in modulating the aggressiveness and differentiation of malignant cells. Advances in single-cell genomics have transformed our ability to analyze the cellular, transcriptional, and epigenetic heterogeneity of human tumors with unprecedented resolution. This Special Issue will highlight recent progress in our understanding of the tumor and immune microenvironments, as well as identifying relevant biomarkers and therapeutic targets, paving the way for breast cancer to become a curable disease.

Guest Editor

Dr. Huaitian Liu

Center for Cancer Research (CCR), National Cancer Institute (NCI),
Bethesda, MD 20892, USA

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/226967

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)